NFKB1 and COVID-19: In line with these findings, clinical evidence highlights the therapeutic potential of NF-κB inhibition in severe COVID-19 [47,48] as well as the use of drugs targeting JAK kinases to ameliorate disease severity [49,50,51]; accordingly, baricitinib, an oral selective inhibitor of JAKs 1 and 2 approved for the treatment of rheumatoid arthritis, is now in use for the treatment of severe patients (COVID-19 Treatment Guidelines Panel.